Long-lasting Analgesia via Targeted *in vivo* Epigenetic Repression of Nav1.7

Ana M. Moreno^a, Glaucilene F. Catroli^b, Fernando Alemán^a, Andrew Pla^a, Sarah A. Woller^{b,c}, Michael Hu^a, Tony Yaksh^{b,*}, Prashant Mali^{a,*}

^aDepartment of Bioengineering, University of California San Diego, CA, USA.

^bDepartment of Anesthesiology, University of California San Diego, CA, USA.

^cPresent address: National Institutes of Neurological Disorder and Stroke, National Institutes of Health, MD, USA.

*Correspondence: pmali@ucsd.edu, tyaksh@ucsd.edu

One sentence summary: *In situ* epigenome engineering approach for genomically scarless, durable, and non-addictive management of pain.

ABSTRACT

Current treatments for chronic pain rely largely on opioids despite their unwanted side effects and risk of addiction. Genetic studies have identified in humans key targets pivotal to nociceptive processing, with the voltage-gated sodium channel, Nav1.7 (SCN9A), being perhaps the most promising candidate for analgesic drug development. Specifically, a hereditary loss-of-function mutation in Nav1.7 leads to insensitivity to pain without other neurodevelopmental alterations. However, the high sequence similarity between Nav subtypes has frustrated efforts to develop selective inhibitors. Here, we investigated targeted epigenetic repression of Nav1.7 via genome engineering approaches based on clustered regularly interspaced short palindromic repeats (CRISPR)-dCas9 and zinc finger proteins as a potential treatment for chronic pain. Towards this end, we first optimized the efficiency of Nav1.7 repression *in vitro* in Neuro2A cells, and then by the lumbar intrathecal route delivered both genome-engineering platforms via adeno-associated viruses (AAVs) to assess their effects in three mouse models of pain: carrageenan-induced inflammatory pain, paclitaxel-induced neuropathic pain and BzATP-induced pain. Our results demonstrate: one, effective repression of Nav1.7 in lumbar dorsal root ganglia; two, reduced thermal hyperalgesia in the inflammatory state; three, decreased tactile allodynia in the neuropathic state; and four, no changes in normal motor function. We anticipate this genomically scarless and non-addictive **pain** amelioration approach enabling **Long-lasting Analgesia via Targeted *in vivo* Epigenetic Repression of Nav1.7**, a methodology we dub **pain LATER**, will have significant therapeutic potential, such as for preemptive administration in

anticipation of a pain stimulus (pre-operatively), or during an established chronic pain state.

INTRODUCTION

Chronic pain affects between 19% to 50% of the world population¹⁻⁴, with more than 100 million people affected in the U.S. alone⁵. Moreover, the number of people reporting chronic pain is expected to increase by 2035 due to the aging global population and prevalence of chronic diseases^{6,7}. While chronic pain is more prevalent than cancer, diabetes and cardiovascular disease combined⁸, drug development has not undergone the remarkable progress seen in these other therapeutic areas. Furthermore, current standard of care for chronic pain often relies on opioids, which can have adverse side effects and significant addiction risk. Despite decades of research, the goal of achieving broadly effective, long-lasting, non-addictive therapeutics for chronic pain has remained elusive.

Pain arising from somatic or nerve injury/pathologies typically arises by activation of populations of primary afferent neurons which are characterized by activation thresholds associated with tissue injury and by sensitivity to products released by local tissue injury and inflammation. These afferents terminate in the spinal dorsal horn, where this input is encoded and transmitted by long ascending tracts to the brain, where it is processed into the pain experience. The cell body of a primary afferent lies in its dorsal root ganglion (DRG). These neuronal cell bodies, synthesize the voltage gated sodium channels that serve to initiate and propagate the action potential⁹⁻¹¹. While local anesthetics can yield a dense anesthesia, previous work has in fact shown that nonspecific sodium channel blockers such as lidocaine delivered systemically at subanesthetic concentrations were able to have selective effects upon hyperpathia in animal models and humans¹²⁻¹⁵.

It is now known that there are nine voltage-gated sodium channel subtypes along with numerous splice variants. Of note, three of these isotypes: Na_v1.7^{16,17}, Na_v1.8¹⁸⁻²⁰, and Na_v1.9^{21,22} have been found to be principally expressed in primary afferent nociceptors. The relevance of these isotypes to human pain has been suggested by the observation that a loss-of-function mutation in Na_v1.7 (SCN9A) leads to congenital insensitivity to pain (CIP), a rare genetic disorder. Conversely, gain of function mutations yield anomalous hyperpathic states²³⁻²⁹. Based on these observations, the Na_v1.7 channel has been considered an attractive target for addressing pathologic pain states

and for developing chronic pain therapies^{17,29–31}. Efforts to develop selective small molecule inhibitors have, however, been hampered due to the sequence similarity between Na_v subtypes. Many small-molecule drugs targeting Na_v1.7 have accordingly failed due to side effects caused by lack of targeting specificity or their bioavailability by the systemic route³². Additionally, antibodies have faced a similar situation, since there is a tradeoff between selectivity and potency due to the binding of a specific (open or close) conformation of the channel, with binding not always translating into successful channel inhibition^{33–36}. Further, it is not clear that such antibodies can gain access to the appropriate Na_v1.7 channels and yield a reliable block of their function. Consequently, in spite of preclinical studies demonstrating that decreased Na_v1.7 activity leads to a reduction in inflammatory and neuropathic pain^{16–22,37}, no molecule targeting this gene product has reached the final phase of clinical trials³². We therefore took an alternative approach by epigenetically modulating the expression of Na_v1.7 using two genome engineering tools, clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 (CRISPR-Cas9) and zinc-finger proteins (ZFP), such that one could engineer highly specific, long-lasting and reversible treatments for pain.

Through its ability to precisely target disease-causing DNA mutations, the CRISPR-Cas9 system has emerged as a potent tool for genome manipulation, and has shown therapeutic efficacy in multiple animal models of human diseases^{38–44}. However, permanent genome editing, leading to permanent alteration of pain perception, may not be desirable. For example, pain can be a discomforting sensory and emotional experience, but it plays a critical role alerting of tissue damage. Permanent ablation could thus have detrimental consequences. For these reasons, we have employed a catalytically inactivated “dead” Cas9 (dCas9, also known as CRISPRi), which does not cleave DNA but maintains its ability to bind to the genome via a guide-RNA (gRNA), and fused it to a repressor domain (Krüppel-associated box, KRAB) to enable non-permanent gene repression of Na_v1.7. Previously, we and others have shown that through addition of a KRAB epigenetic repressor motif to dCas9, gene repression can be enhanced with a high level of specificity both *in vitro*^{45–49} and *in vivo*^{50,51}. This transcriptional modulation system takes advantage of the high specificity of CRISPR-Cas9 while simultaneously increasing the safety profile, as no permanent modification of the genome is performed. As a second approach for *in situ* epigenome repression of Na_v1.7, we also utilized zinc-finger-KRAB proteins (ZFP-KRAB), consisting of a DNA-binding domain made up of Cys₂His₂ zinc fingers fused to a KRAB repressor. ZFP

constitute the largest individual family of transcriptional modulators encoded by the genomes of higher organisms⁵², and with prevalent synthetic versions engineered on human protein chasses present a potentially low immunogenicity *in vivo* targeting approach^{53–55}. We sought to produce a specific anatomic targeting of the gene regulation by delivering both epigenetic tools in an adeno-associated virus (AAV) construct into the spinal intrathecal space. Of note, many AAVs have been shown to produce a robust transduction of the dorsal root ganglion^{56–58}. This approach has several advantages as it permits the use of minimal viral loads and reduces the possibility of systemic immunogenicity.

Since pain perception is etiologically diverse and multifactorial, several rodent pain models have been utilized to study pain signaling and pain behaviors⁵⁹. In the present work we sought to characterize the effects of CRISPR-mediated knock down of Na_v1.7 using three mechanistically distinct models: i) thermal sensitivity in control (normal) and unilateral inflammation-sensitized hind paw; ii) a poly neuropathy induced by a chemotherapeutic yielding a bilateral hind paw tactile allodynia and, iii) a spinally evoked bilateral hind paw tactile allodynia induced by spinal activation of purine receptors. Pain due to tissue injury and inflammation results from a release of factors that sensitize the peripheral terminal of the nociceptive afferent neuron. This phenotype can be studied through local application of carrageenan to the paw resulting in inflammation, swelling, increased expression of Na_v1.7⁶⁰ and a robust increase in thermal and mechanical sensitivity (hyperalgesia)^{61,62}. Chemotherapy to treat cancer often leads to a polyneuropathy characterized by increased sensitivity to light touch (e.g. tactile allodynia) and cold. Paclitaxel is a commonly used chemotherapeutic that increases the expression of Na_v 1.7 in the nociceptive afferents^{63,64} and induces a robust allodynia in the animal models^{65–67}. Finally, ATP (adenosine triphosphate) by an action on a variety of purine receptors expressed on afferent terminals and second order neurons and non neuronal cells has been broadly implicated in inflammatory, visceral and neuropathic pain states^{57–60}. Thus, intrathecal delivery of a stable ATP analogue (BzATP: 2',3'-O-(4-benzoylbenzoyl)-ATP) results in a long-lasting allodynia in mice^{71,72}.

Thus, we first tested various KRAB-dCas9 and ZFP-KRAB constructs in a mouse neuroblastoma cell line that expresses Na_v1.7 (Neuro2a) and optimized repression levels. We next packaged the constructs with the strongest *in vitro* repression into AAV9 and injected these intrathecally into adult C57BL/6J mice. After 21 days, we induced paw inflammation via injection of carrageenan, and tested for thermal hyperalgesia. Our

results demonstrated *in vivo* repression of Na_v1.7 and a decrease in thermal hyperalgesia. Similarly, we tested our epigenome strategy in two neuropathic pain models: chemotherapy-induced (paclitaxel) and BzATP-induced neuropathic pain. The results in the paclitaxel-induced neuropathic pain model indicate that repression of Na_v1.7 leads to reduced tactile and cold allodynia. In addition, KRAB-dCas9 injected mice showed reduced tactile allodynia after administration of the ATP analogue BzATP. As many pain states occurring after chronic inflammation and nerve injury represent an enduring condition, typically requiring constant re-medication, these genetic approaches provide ongoing and controllable regulation of this aberrant processing. Overall, these *in situ* epigenetic approaches could represent a viable replacement for opioids and serve as a potential therapeutic approach for long lasting chronic pain.

RESULTS

In vitro optimization of epigenetic engineering tools to enable Na_v1.7 repression.

With the goal of developing a therapeutic product that relieves chronic pain in a non-permanent, non-addictive and long-lasting manner, we explored the use of two independent genetic approaches to inhibit the transmission of pain at the spinal level (**Figure 1a**). To establish robust Na_v1.7 repression, we first compared *in vitro* repression efficacy of Na_v1.7 using KRAB-dCas9 and ZFP-KRAB constructs. Towards this, we cloned ten guide-RNAs (gRNAs; **Supplementary Table 1**) —designed by an *in silico* tool⁷³ that predicts highly effective gRNAs based on chromatin position and sequence features— into our previously developed split-dCas9 platform⁵⁰. We also cloned the two gRNAs that were predicted to have the highest efficiency (SCN9A-1 and SCN9A-2) into a single construct, since we have previously shown that higher efficacy can be achieved by using multiple gRNAs⁵⁰. We next utilized four ZFP-KRAB constructs targeting the Na_v1.7 DNA sequence (**Supplementary Table 2**). These constructs were transfected into a mouse neuroblastoma cell line that expresses Na_v1.7 (Neuro2a) and we confirmed repression of Na_v1.7 relative to GAPDH with qPCR. Six of ten gRNAs repressed the Na_v1.7 transcript by >50% compared to the non-targeting gRNA control, with gRNA-2 being the single gRNA having the highest repression (56%) and with the dual-gRNA having repression levels of 71% ($p < 0.0001$), which we utilized for subsequent *in vivo* studies (**Supplementary Figure 1a**). Of the ZFP-KRAB designs, the Zinc-Finger-4-KRAB construct had the highest repression (88%; $p < 0.0001$) compared to the negative control (mCherry), which we chose for subsequent *in vivo* studies

(Supplementary Figure 1a). Western blotting confirmed a corresponding decrease in protein level for both the Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA groups **(Supplementary Figure 1b).**

In vivo evaluation of ZFP-KRAB and KRAB-dCas9 treatment efficacy in a carrageenan model of inflammatory pain

Having established *in vitro* Nav1.7 repression, we next focused on testing the effectiveness of the best ZFP-KRAB and KRAB-dCas9 constructs from the *in vitro* screens (Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA) in a carrageenan-induced model of inflammatory pain. Mice were intrathecally (i.t.) injected with 1E+12 vg/mouse of AAV9-mCherry (negative control; n=10), AAV9- Zinc-Finger-4-KRAB (n=10), AAV9-KRAB-dCas9-no-gRNA (negative control; n=10) and AAV9-KRAB-dCas9-dual-gRNA (n=10). The intrathecal delivery of AAV9, which has significant neuronal tropism⁵⁸, serves to efficiently target DRG **(Supplementary Figure 2a)**. After 21 days, thermal pain sensitivity was measured to establish a baseline response threshold. Inflammation was induced in all four groups of mice by injecting one hind paw with carrageenan (ipsilateral), while the other hind paw (contralateral) was injected with saline to serve as an in-mouse control. Mice were then tested for thermal pain sensitivity at 30 minutes, 1, 2, 4, and 24 hours after carrageenan injection **(Figure 1b)**. Twenty-four hours after carrageenan administration, mice were euthanized and DRG (L4-L6) were extracted. The expression levels of Nav1.7 was determined by qPCR, and a significant repression of Nav1.7 was observed in mice injected with AAV9-Zinc-Finger-4-KRAB (67%; p=0.0008) compared to mice injected with AAV9-mCherry, and in mice injected with AAV9-KRAB-dCas9-dual-gRNA (50%; p=0.0033) compared to mice injected with AAV9-KRAB-dCas9-no-gRNA **(Figure 1c)**. The mean paw withdrawal latencies (PWL) were calculated for both carrageenan and saline injected paws **(Supplementary Figure 2b, c)** and the area under the curve (AUC) for the total mean PWL was calculated. As expected, compared to saline-injected paws, carrageenan-injected paws developed thermal hyperalgesia, measured by a decrease in PWL after application of a thermal stimulus **(Figure 1d)**. We also observed a significant increase in PWL in mice injected with either AAV9-Zinc-Finger-4-KRAB or AAV9-KRAB-dCas9-dual-gRNA, indicating that the repression of Nav1.7 in mouse DRG leads to lower thermal hyperalgesia in an inflammatory pain state. The thermal latency of the control (un-inflamed paw) was not significantly different across AAV treatment groups, indicating that the knock down of the

Na_v1.7 had minimal effect upon normal thermal sensitivity. As an index of edema/inflammation, we measured the ipsilateral and contralateral paws with a caliper before and 4 hours after carrageenan injection, which is the time point with the highest thermal hyperalgesia. We observed significant edema formation in both experimental and control groups, indicating that Na_v1.7 repression has no effect on inflammation (**Supplementary Figure 2d**).

Benchmarking in vivo ZFP-KRAB treatment efficacy with established small molecule drug gabapentin in a carrageenan model of inflammatory pain

To validate the efficacy of ZFP-KRAB in ameliorating thermal hyperalgesia in a carrageenan model of inflammatory pain, we next conducted a separate experiment and tested the small molecule drug gabapentin as a positive control. Mice were i.t. injected with 1E+12 vg/mouse of AAV9-mCherry (n=5), AAV9-Zinc-Finger-4-KRAB (n=6), or saline (n=5). After 21 days, thermal nociception was measured in all mice as previously described. One hour before carrageenan administration, the mice that received intrathecal saline were injected as a positive comparator with intraperitoneal (i.p.) gabapentin (100 mg/kg). This agent is known to reduce carrageenan-induced thermal hyperalgesia in rodents through binding to spinal alpha2 delta subunit of the voltage gated calcium channel^{74,75}. Twenty-four hours after carrageenan administration, mice were euthanized and DRG (L4-L6) were extracted. The expression levels of Na_v1.7 were determined by qPCR, and a significant repression of Na_v1.7 was observed in AAV9-Zinc-Finger-4-KRAB (**p=0.0007) and in the gabapentin groups (*p=0.0121) (**Supplementary Figure 3a**). We measured the ipsilateral and contralateral paws with a caliper before and 4 hours after carrageenan injection, and confirmed significant edema formation in the injected paw of all groups as compared to the non-injected paw in all groups (**Supplementary Figure 3b**). The mean PWL was calculated for both carrageenan and saline injected paws (**Figure 2b, c**). We then compared paw withdrawal latencies of carrageenan injected paws for AAV9-Zinc-Finger-4-KRAB and gabapentin groups at each time point to the AAV9-mCherry carrageenan injected control using a two-way ANOVA calculation to determine whether there was any significant reduction in thermal hyperalgesia (**Supplementary Figure 3c**). When comparing carrageenan-injected hind paws, we observed that only AAV9-Zinc-Finger-4-KRAB had significantly higher PWL at all the time points following carrageenan injection when compared to the AAV9-mCherry control. We also observed significance in PWL for the

gabapentin positive control group at the 30 minute, 1 hour, and four hour time points, but not the 24 hour time point. This result reflects the half-life of gabapentin (3-5 hours). We then calculated the area under the curve (AUC) for thermal hyperalgesia. We observed a significant increase in PWL in the carrageenan-injected gabapentin group ($p=0.0208$) (**Figure 2b**), and in the Zinc-Finger-4-KRAB group (115% improvement, $p=0.0021$) (**Figure 2c**) compared to the carrageenan-injected AAV9-mCherry control. In addition, the AAV9-Zinc-Finger-4-KRAB group had 31% higher PWL than the gabapentin positive control group. Of note, the thermal escape latency of the contralateral non-inflamed paw showed no significant difference among groups.

In vivo repression of $Na_v1.7$ leads to amelioration of pain in a poly neuropathic pain model

After having established *in vivo* efficacy in an inflammatory pain model, we went on to validate our epigenome repression strategy for neuropathic pain using the polyneuropathy model by the chemotherapeutic paclitaxel. To establish this model, mice were first injected with $1E+12$ vg/mouse of AAV9-mCherry ($n=8$), AAV9-Zinc-Finger-4-KRAB ($n=8$), AAV9-KRAB-dCas9-dual-gRNA ($n=8$), AAV9-KRAB-dCas9-no-gRNA ($n=8$), or saline ($n=16$). 14 days later and before paclitaxel administration, we established a baseline for tactile threshold (von Frey filaments). Mice were then administered paclitaxel at days 14, 16, 18, and 20, with a dosage of 8 mg/kg (total cumulative dosage of 32 mg/kg), with a group of saline injected mice not receiving any paclitaxel ($n=8$) to establish the tactile allodynia caused by the chemotherapeutic. 21 days after the initial injections and one hour before testing, a group of saline injected mice ($n=8$) were injected with i.p. gabapentin (100 mg/kg). Mice were then tested for tactile allodynia via von Frey filaments and for cold allodynia via acetone testing (**Figure 3a**). A 50% tactile threshold was calculated. We observed a decrease in tactile threshold in mice receiving AAV9-mCherry and AAV9-KRAB-dCas9-no-gRNA, while mice that received gabapentin, AAV9-Zinc-Finger-4-KRAB, and AAV9-KRAB-dCas9-dual-gRNA had increased withdrawal thresholds, indicating that *in situ* $Na_v1.7$ repression leads to amelioration in chemotherapy induced tactile allodynia (**Figure 3b**). Similarly, an increase in the number of withdrawal responses is seen in mice tested for cold allodynia in the negative control groups (AAV9-mCherry and AAV9-KRAB-dCas9-no-gRNA), while both AAV9-Zinc-Finger-4-KRAB and AAV9-KRAB-dCas9-dual-gRNA groups had a decrease in withdrawal responses, indicating that *in situ* repression of $Na_v1.7$ also leads to a decrease in chemotherapy induced cold allodynia (**Figure 3c**).

In vivo repression of Na_v1.7 leads to amelioration of pain in a model of spinal evoked pain.

We next tested whether *in situ* repression of Na_v1.7 via KRAB-dCas9 could ameliorate neuropathic pain induced by BzATP. This molecule activates P2X receptors located on central terminals leading to a centrally mediated hyperalgesic state. We first injected mice with 1E+12 vg/mouse of AAV9-mCherry (n=6), AAV9-KRAB-dCas9-no-gRNA (n=5), and AAV9-KRAB-dCas9-dual-gRNA (n=6). After 21 days, tactile thresholds were determined with von Frey filaments, and mice were injected i.t. with BzATP (30 nmol). Tactile allodynia was then measured at 30 min, 1, 2, 3, 6, and 24 hours after BzATP administration (**Figure 3d**). We observed a significant decrease in tactile allodynia at 30 min, 1 and 2 hour time points in mice injected with AAV9-KRAB-dCas9-dual-gRNA, and an overall increase in tactile threshold at all time points (**Figure 3e**).

Durable pain amelioration via the in situ repression of Na_v1.7 with Zinc-Finger-KRAB and KRAB-dCas9

To determine whether *in situ* repression of Na_v1.7 was efficacious long-term, we repeated the carrageenan inflammatory pain model and tested thermal hyperalgesia at 21 and 42 days after i.t. AAV injection (n=8/group) (**Figure 4a**). We observed a significant improvement in PWL for carrageenan-injected paws in Zinc-Finger-4-KRAB groups at both day 21 (**Supplementary Figure 3d**) and day 42 (**Figure 4b**) demonstrating the durability of this approach. To determine whether *in situ* repression of Na_v1.7 was also efficacious long-term in a poly neuropathic pain model, we measured tactile and cold allodynia 49 days after initial AAV injections and 29 days after the last paclitaxel injection (total cumulative dosage of 32 mg/kg; **Figure 4c**). Compared to the earlier time point (**Figure 3b, c**), we observed that mice from both AAV9-mCherry (n=8) and AAV9-KRAB-dCas9-dual-gRNA (n=8) groups had increased tactile allodynia at day 49 as compared to day 21, and responded to the lowest von Frey filament examined (0.04 g). In comparison, mice receiving AAV9-Zinc-Finger-4-KRAB and AAV9-KRAB-dCas9-dual-gRNA had increased withdrawal thresholds, indicating that *in situ* Na_v1.7 repression leads to long-term amelioration in chemotherapy-induced tactile allodynia (**Figure 4d**). As before, an increase in the number of withdrawal responses is seen in mice tested for cold allodynia in the negative control groups (AAV9-mCherry and AAV9-KRAB-dCas9-no-gRNA), while both AAV9-Zinc-Finger-4-KRAB and AAV9-KRAB-dCas9-dual-gRNA groups had a decrease in withdrawal responses, indicating that *in situ*

repression of Na_v1.7 also leads long-term amelioration of chemotherapy induced cold allodynia (**Figure 4e**)

DISCUSSION

In this study, we investigated the efficacy of the repression of Na_v1.7 in the dorsal root ganglia using two independent genome engineering platforms —KRAB-dCas9 and Zinc-Finger-KRAB proteins— to treat acute and persistent nociceptive processing generated in murine models of peripheral inflammation and poly neuropathy. We believe the promising results suggest the utility of the approach for developing a therapeutic reagent.

Development of targeted constructs

The work employed multiple guide-RNAs (gRNAs) clones which were rationally designed using an *in silico* tool⁷³ that predicts effective gRNAs based on chromatin position and sequence features into the split-dCas9 platform⁵⁰. Similarly, we devised multiple ZFP-KRAB Na_v1.7 DNA targeting constructs. These constructs were transfected into a murine neuroblastoma cell line that expresses Na_v1.7 (Neuro2a) and repression of Na_v1.7 was confirmed. Constructs showing the highest level of repression were chosen for subsequent *in vivo* studies.

Although other technologies, such as RNAi have been utilized to target Na_v1.7, a recent study has shown that the off-target effects of RNAi, as compared to CRISPRi, are far stronger and more pervasive than generally appreciated^{76,77}. In addition, as an exogenous system, CRISPR and ZFPs (unlike RNAi) do not compete with endogenous machinery such as microRNA or RISC complex function. Thus, RNAi can have an impact in the regular homeostatic mechanisms of RNA synthesis and degradation. In addition, CRISPR and ZFP methods target genomic DNA instead of RNA, which means that to achieve an effect, RNAi methods require a higher dosage with poorer pharmacokinetics prospects, as there is usually a high RNA turnover⁴⁶.

In vivo spinal Na_v1.7 knock down

In these studies, we found that mice injected with either epigenetic platform had significantly reduced DRG expression of Na_v1.7. Other studies have shown that partial repression of Na_v1.7^{78–83} is sufficient to ameliorate pain. This knock down serves to produce a significant reversal of the hyperalgesia induced by hind paw inflammation.

Using antisense oligonucleotides, mechanical pain could be ameliorated with 30 to 80% $\text{Na}_v1.7$ repression levels⁸¹. Using microRNA 30b, around 50% repression of $\text{Na}_v1.7$ relieved neuropathic pain⁸², while more recently microRNA182 ameliorated pain preventing $\text{Na}_v1.7$ overexpression in spared nerve injury rats⁷⁹. Similarly, shRNA mediated knockdown of $\text{Na}_v1.7$ prevented its overexpression in burn injury relieving pain⁷⁸. Other studies did not quantify the $\text{Na}_v1.7$ repression levels needed to reduce pain⁸⁰. Additionally, shRNA lentiviral vectors can reduce bone cancer pain by repressing $\text{Na}_v1.7$ 40 to 60%⁸³. Further studies are needed to determine what the minimum dosage to have an effect is.

The role of $\text{Na}_v1.7$ has been implicated in a variety of preclinical models, including those associated with robust inflammation as in the rodent carrageenan and CFA model. We examined the effect of knocking down $\text{Na}_v1.7$ in a paclitaxel-induced poly neuropathy. Previous work has shown that this treatment will induce $\text{Na}_v1.7$ ^{64,87}. Both epigenetic repressors ameliorate tactile allodynia to the same extent as the internal comparator gabapentin. Finally, we further addressed the role of $\text{Na}_v1.7$ knock down in hyperpathia induced by i.t. injection of BzATP. This was significantly attenuated in mice previously treated with KRAB-dCas9. Spinal purine receptors have been shown to play a pivotal role in the nociceptive processing initiated by a variety of stimulus conditions including inflammatory/incisional pain and a variety of neuropathies^{72,88-90}. The present observations suggest that the repression of afferent $\text{Na}_v1.7$ expression in the nociceptor leads to a suppression of enhanced tactile sensitivity induced centrally. The mechanism underlying these results may reflect upon the observation that down regulation of $\text{Na}_v1.7$ in the afferent may serve to minimize the activation of microglia and astrocytes⁸³. These results suggest that, at least partially, pain signal transduction through $\text{Na}_v1.7$ is downstream of ATP signaling.

We chose gabapentin as a positive control due to evidence that it decreases carrageenan-induced thermal hyperalgesia in rodents and because it is known to repress $\text{Na}_v1.7$. Our results are consistent with previous studies that showed an inhibitory effect of gabapentin on $\text{Na}_v1.7$ expression levels, ultimately leading to a reduction of neuronal excitability⁹¹. In addition, although it has been previously reported that gabapentin can lower inflammation on rat paw edema induced by carrageenan⁹², we did not find any reduction in inflammation in the gabapentin group. This could be due to a difference in animal model, gabapentin dosage, or the concentration of carrageenan injected. Because only one dosage of gabapentin was utilized for these experiments, an

additional group of mice receiving a different gabapentin dosage or with a second dosage can be utilized as a secondary positive control.

Of note, these drug effects examined in the polyneuropathy and carrageenan model appeared to persist unchanged for at least 6-7 weeks. Long term expression has been similarly noted in other gene therapy studies^{57,93–95}. Importantly, these effects were unaccompanied by any detectable adverse motor effects or changes in bladder function.

Spinal route for therapeutic delivery

The presented research shows efficacy of spinal reduction in Na_v1.7 in three models of hyperpathia using two complementary epigenetic tools. These studies clearly established significant target engagement and clear therapeutic efficacy with no evident adverse events after intrathecal knock down of Na_v1.7 with two independent platforms. The intrathecal route of delivery represents an appropriate choice for this therapeutic approach. The role played by Na_v1.7 is in the nociceptive afferents, and their cell bodies are in the respective segmental DRG neurons. Accordingly, the DRG represents the target for this transfection motif. The intrathecal delivery route efficiently place AAVs to the DRG neurons which minimizes the possibility of off target biodistribution and reduces the viral load required to get transduction. Importantly, the relative absence of B and T cells^{96,97} in the cerebrospinal fluid, reduces the potential immune response. In this regard, as ZFPs are engineered on human protein chasses, they intrinsically constitute a targeting approach with even lower potential immunogenicity. Indeed, a study in non-human primates (NHP) found that intrathecal delivery of a non-self protein (AAV9-GFP) produced immune responses which were not seen with the delivery of a self-protein⁹⁸.

Future directions

These results displaying target engagement and efficacy provide strong support for the development of these platforms for pain control. Several issues are pertinent: One, further studies are needed to determine what is the minimum effective AAV dosage to produce knock down and therapeutic effects. Two, this work showed reduction in Na_v1,7 at 21, 42, and 49 days after AAV injections and corresponding changes in pain behavior. However, still longer-term studies need to be performed to evaluate the actual duration of treatment and whether any compensatory mechanisms take place due to

Nav1.7 repression. Three, further studies must be performed to explore the properties of repeat-dosing. Four, we validated our approach in three mouse pain models. However, other models of inflammatory pain should be tested to further validate our results. Carrageenan produces a model of persistent pain and hyperalgesia that best represents an acute phase from 1-24 hours and that converts to chronic inflammation by two weeks⁶¹. Therefore, the performed experiments can be repeated two-weeks after administering carrageenan to determine efficacy in a chronic inflammatory pain state. The Complete Freund's adjuvant (CFA) model, collagen type II antibodies (CAIA) or K/BxN transgenic mice mimic the pathology of rheumatoid arthritis such as: widespread inflammation with the greatest effect distally, cartilage degradation, and elevated inflammatory cytokines in the joint fluid, and are thus additional important models to explore⁵⁹. Focus on visceral pain will also be an important direction moving forward. Finally, five, other species including rats must be explored to further validate this approach.

Therapeutic utility of intrathecal CRISPR/ZFP.

As a potential clinical treatment, KRAB-dCas9 and ZFP-KRAB show promise for treating chronic inflammatory and neuropathic pain. These systems allow for potentially reversible gene therapy, which is advantageous in the framework of chronic pain, as permanent pain insensitivity is not desired. Additionally, the weeks-long duration presents a significant advantage compared to existing drugs which must be taken daily or hourly, and which may have undesirable addictive effects. Taken together, the results of these studies show a promising new avenue for treatment of chronic pain, a significant and increasingly urgent issue in our society. For instance, cancer treatment related side effects, and in particular chemotherapy induced polyneuropathy is one of the most common adverse events which could potentially be targeted using this system^{101,102}. In this instance, a therapeutic approach that endures for months is preferable to one that is irreversible. Furthermore, the use of multiple neuraxial interventions over time is a common motif for clinical interventions as with epidural steroids where repeat epidural delivery may occur over the year at several month intervals¹⁰³. Taken together, we anticipate this genomically scarless and non-addictive pain amelioration approach enabling long-lasting analgesia via targeted *in vivo* epigenetic repression of Nav1.7, will have significant therapeutic potential, such as

for preemptive administration in anticipation of a pain stimulus (pre-operatively), or during an established chronic pain state.

ACKNOWLEDGEMENTS

We thank members of the Mali lab for advice and help with experiments, and the Salk GT3 viral core for help with AAV production. This work was supported by UCSD Institutional Funds and NIH grants (R01HG009285, RO1CA222826, RO1GM123313). A.M. acknowledges a graduate fellowship from CONACYT and UCMEXUS. GFC thanks FAPESP (grant 2018/05778-3).

AUTHOR CONTRIBUTIONS

A.M. conceived and performed experiments, analyzed data and wrote the manuscript. G.C. performed the BzATP experiments. F.A. performed experiments, analyzed data and wrote the manuscript. A.P., P.M., M.H. performed experiments. S.W. helped setup and design experiments. P.M. and T.Y. supervised the project, conceived and designed experiments, and wrote the manuscript. This article was prepared while Sarah A. Woller was employed at the University of California, San Diego. The opinions expressed in this article are the author's own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government.

COMPETING INTERESTS

A.M., F.A., T.Y. and P.M. have filed patents based on this work. TY is a member of the SAB for Navega Therapeutics. A.M. is a co-founder of Navega Therapeutics. P.M. is a scientific co-founder of Shape Therapeutics, Boundless Biosciences, Seven Therapeutics, Navega Therapeutics, and Engine Biosciences. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

Figure 1: *In situ* repression of Na_v1.7 leads to pain amelioration in a carrageenan model of inflammatory pain. (a) Schematic of the overall strategy used for *in situ* Na_v1.7 repression using ZFP-KRAB and KRAB-dCas9. Na_v1.7 is a DRG channel involved in the transduction of noxious stimuli into electric impulses at the peripheral terminals of DRG neurons. *In situ* repression of Na_v1.7 via AAV-ZFP-KRAB and AAV-KRAB-dCas9 is achieved through intrathecal injection leading to disruption of the pain signal before reaching the brain. (b) Schematic of the carrageenan-induced inflammatory pain model. At day 0, mice were intrathecally injected with either AAV9-Zinc-Finger-4-KRAB, AAV9-mCherry, AAV9-KRAB-dCas9-dual-gRNA or AAV9-KRAB-dCas9-no-gRNA. 21 days later, thermal pain sensitivity was measured in all mice with the Hargreaves assay. In order to establish a baseline level of sensitivity, mice were tested for tactile threshold using von Frey filaments before carrageenan injection. Mice

were then injected with carrageenan in their left paw (ipsilateral) while the right paw (contralateral) was injected with saline as an in-mouse control. They were then tested for thermal paw-withdrawal latency at 30 min, 1, 2, 4, and 24 hours after carrageenan administration. **(c)** *In vivo* Na_v1.7 repression efficiencies: Twenty-four hours after carrageenan administration, mice DRG (L4-L6) were harvested and Na_v1.7 repression efficacy was determined by qPCR. (n=5; error bars are SEM; Student's t-test; ***p = 0.0008, **p=0.0033). **(d)** The aggregate paw withdrawal latency was calculated as area under the curve (AUC) for both carrageenan and saline injected paws. Mice treated with Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA had significant increased paw-withdrawal latencies in carrageenan-injected paws (n=10; error bars are SEM; Student's t-test, ****p < 0.0001).

Figure 2: Benchmarking of *in situ* repression of Nav1.7 using Zinc-Finger-KRAB with established small molecule drug gabapentin. (a) Schematic of the experimental approach. **(b)** Time course of thermal hyperalgesia after the injection of carrageenan (solid lines) or saline (dotted lines) into the hind paw of mice injected with gabapentin (100mg/kg) and mCherry and Zinc-Finger-4-KRAB are plotted. Mean paw withdrawal latencies (PWL) are shown. The AUC of the thermal-hyperalgesia time-course are plotted on the right panels. A significant increase in PWL is seen in the carrageenan-injected paws of mice injected with gabapentin and Zinc-Finger-4-KRAB (n=5 for mCherry and gabapentin and n=6 for Zinc-Finger-4-KRAB; error bars are SEM; Student's t-test, *p = 0.0208, **p=0.0021).

Figure 3: *In vivo* efficacy of Zinc-Finger-KRAB and KRAB-dCas9 in two neuropathic pain models (a) Schematic of the paclitaxel-induced neuropathic pain model. Mice were i.t. injected with AAV9-mCherry, AAV9-Zinc-Finger-4-KRAB, AAV9-KRAB-dCas9-no-gRNA, AAV9-KRAB-dCas9-dual-gRNA or saline. Following baseline von Frey threshold testing at day 14, mice were then injected i.p. with 8mg/kg of

paclitaxel at 14, 16, 18, 20 days after i.t. injection. 21 days after i.t. injection, mice were tested for tactile allodynia via von Frey filaments and for cold allodynia via the application of acetone. **(b)** *In situ* repression of Nav1.7 via Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA reduces paclitaxel-induced tactile allodynia. (n=8; error bars are SEM; Student's t-test; ***p = 0.0007, ***p = 0.0004) **(c)** *In situ* repression of Nav1.7 via Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA reduces paclitaxel-induced cold allodynia. (n=8; error bars are SEM; Student's t-test; ****p < 0.0001, **p = 0.008). **(d)** Schematic of the BzATP pain model. Mice were injected at day 0 with AAV9-mCherry, AAV9-KRAB-dCas9-no-gRNA or AAV9-KRAB-dCas9-dual-gRNA. 21 days later, mice were baselined for von Frey tactile threshold and were then i.t. injected with 30 nmol BzATP. 30 minutes, 1, 2, 3, 6, and 24 hours after BzATP administration, mice were tested for tactile allodynia. **(e)** *In situ* repression of Nav1.7 via KRAB-dCas9-dual-gRNA reduces tactile allodynia in a BzATP model of neuropathic pain (n=5 for KRAB-dCas9-no-gRNA and n=6 for the other groups, two-way ANOVA with Bonferonni *post-hoc* test; ****p < 0.0001, *p = 0.0469).

Figure 4: Long-term efficacy of Zinc-Finger-KRAB and KRAB-dCas9 in two independent pain models. (a) Timeline of the carrageenan-induced inflammatory pain model. **(b)** Time course of thermal hyperalgesia after the injection of carrageenan (solid lines) or saline (dotted lines) into the hind paw of mice 42 days after i.t. injection with AAV9-mCherry and AAV9-Zinc-Finger-4-KRAB are plotted. Mean paw withdrawal

latencies are shown. The AUC of the thermal-hyperalgesia time-course are plotted on the right panel. A significant increase in PWL is seen in the carrageenan-injected paws of mice injected with AAV9-Zinc-Finger-4-KRAB (n=8; error bars are SEM; Student's t-test; ****p < 0.0001). **(c)** Schematic of the paclitaxel-induced neuropathic pain model. **(d)** *In situ* repression of Na_v1.7 via Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA reduces paclitaxel-induced tactile allodynia 49 days after last paclitaxel injection (n=7 for Zinc-Finger-4-KRAB and n=8 for other groups; error bars are SEM; Student's t-test; ****p < 0.0001). **(e)** *In situ* repression of Na_v1.7 via Zinc-Finger-4-KRAB and KRAB-dCas9-dual-gRNA reduces paclitaxel-induced cold allodynia. (n=7 for Zinc-Finger-4-KRAB and n=8 for other groups; error bars are SEM; Student's t-test; ****p < 0.0001, ***p = 0.0001).

a

b

Supplementary Figure 1: *In vitro* optimization of epigenetic genome engineering tools to enable Nav1.7 repression. (a) A panel of four zinc finger proteins and ten gRNAs were designed to target Nav1.7 in a mouse neuroblastoma cell line (Neuro2a) and were screened for repression efficacy by qPCR. A non-targeting gRNA (no gRNA) was used as a control for KRAB-dCas9 constructs targeting Nav1.7, while mCherry was used as a control for ZFP-KRAB constructs targeting Nav1.7 (n=3; error bars are SEM; one-way ANOVA; ****p < 0.0001). **(b)** *In vitro* western blotting of Nav1.7 in Neuro2a cells transfected with mCherry, Zinc-Finger-2-KRAB, Zinc-Finger-4-KRAB, KRAB-dCas9-no-gRNA, KRAB-dCas9-dual-gRNA (1+2), and KRAB-dCas9-gRNA-8+10.

Supplementary Figure 2: *In situ* repression of Na_v1.7 leads to pain amelioration in a carrageenan model of inflammatory pain. (a) Confirming AAV9-mCherry transduction in mice DRG via RNA FISH (red= mCherry, pink= Na_v1.7; scale bar=50μm). (b) Time course of thermal hyperalgesia after the injection of carrageenan (solid lines) or saline (dotted lines) into the hind paw of mice 21 days after i.t. injection

with AAV9-KRAB-dCas9-no-gRNA and AAV9-KRAB-dCas9-dual-gRNA are plotted. Mean paw withdrawal latencies are shown. (n=10; error bars are SEM). **(c)** Time course of thermal hyperalgesia after the injection of carrageenan (solid lines) or saline (dotted lines) into the hind paw of mice 21 days after i.t. injection with AAV9-mCherry and AAV9-Zinc-Finger-4-KRAB are plotted. Mean paw withdrawal latencies are shown. (n=10; error bars are SEM). **(d)** Paw thickness of ipsilateral paws at baseline and four hours after carrageenan injection are plotted (n=10).

Supplementary Figure 3: Evaluation of Zinc-Finger-KRAB in an inflammatory model of pain. (a) *In vivo* Nav_v1.7 repression efficiencies from treated mice DRG. Twenty-four hours after carrageenan administration, mice DRG (L4-L6) were harvested and Nav_v1.7 repression efficacy was determined by qPCR. (n=5 for mCherry and Gabapentin groups and n=6 for Zinc-Finger-4-KRAB group; error bars are SEM; one way ANOVA with Dunnet's *post hoc* test; ***p = 0.0007, *p=0.0121). (b) Paw thickness of ipsilateral paws at baseline and four hours after carrageenan injection are plotted. (c) Significance of paw withdrawal latencies in mice receiving AAV9-Zinc-Finger-4-KRAB

and gabapentin (100 mg/kg) as compared to AAV9-mCherry carrageenan-injected paw (negative control). Two-way ANOVA with Bonferroni *post hoc* test. **(d)** Independent repeat of experiment in **(a)**: time course of thermal hyperalgesia after the injection of carrageenan (solid lines) or saline (dotted lines) into the hind paw of mice 21 days after i.t. injection with AAV9-mCherry and AAV9-Zinc-Finger-4-KRAB are plotted. Mean paw withdrawal latencies are shown. The AUC of the thermal-hyperalgesia time-course are plotted on the right panel. A significant increase in PWL is seen in the carrageenan-injected paws of mice injected with AAV9-Zinc-Finger-4-KRAB (n=8; error bars are SEM; Student's t-test; ****p < 0.0001).

Supplementary Table 1: CRISPR-Cas9 guide RNA spacer sequences

gRNA	Sequence
SCN9A-1	ACAGTGGGCAGGATTGAAA
SCN9A-2	GCAGGTGCACTCACCGGGT
SCN9A-3	GAGCTCAGGGAGCATCGAGG
SCN9A-4	AGAGTCGCAATTGGAGCGC
SCN9A-5	CCAGACCAGCCTGCACAGT
SCN9A-6	GAGCGCAGGCTAGGCCTGCA
SCN9A-7	CTAGGAGTCCGGGATACCC
SCN9A-8	GAATCCGCAGGTGCACTCAC
SCN9A-9	GACCAGCCTGCACAGTGGGC
SCN9A-10	GCGACGCGGTTGGCAGCCGA

Supplementary Table 2: Zinc finger protein genomic target sequences

ZF Name	ZF Target Sequence
ZF1	GGCGAGGTGATGGAAGGG
ZF2	GAGGGAGCTAGGGGTGGG
ZF3	AGTGCTAATGTTTCCGAG
ZF4	TAGACGGTGCAGGGCGGA

MATERIALS AND METHODS

Vector Design and Construction

Cas9 and Zinc-Finger AAV vectors were constructed by sequential assembly of corresponding gene blocks (Integrated DNA Technologies) into a custom synthesized rAAV2 vector backbone. gRNA sequences were inserted into dNCas9 plasmids by cloning oligonucleotides (IDT) encoding spacers into AgeI cloning sites via Gibson assembly. gRNAs were designed utilizing an *in silico* tool to predict gRNAs⁷³.

Mammalian Cell Culture

Neuro2a cells were grown in EMEM supplemented with 10% fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific) in an incubator at 37°C and 5% CO₂ atmosphere.

Lipid-Mediated Cell Transfections

One day prior to transfection, Neuro2a cells were seeded in a 24-well plate at a cell density of 1 or 2E+5 cells per well. 0.5 µg of each plasmid was added to 25 µL of Opti-MEM medium, followed by addition of 25 µL of Opti-MEM containing 2 µL of Lipofectamine 2000. The mixture was incubated at room temperature for 15 min. The entire solution was then added to the cells in a 24-well plate and mixed by gently swirling the plate. Media was changed after 24 h, and the plate was incubated at 37°C for 72 h in a 5% CO₂ incubator. Cells were harvested, spun down, and frozen at 80°C.

Production of AAVs

Virus was prepared by the Gene Transfer, Targeting and Therapeutics (GT3) core at the Salk Institute of Biological Studies (La Jolla, CA) or in-house utilizing the GT3 core protocol. Briefly, AAV2/1, AAV2/5, and AAV2/9 virus particles were produced using HEK293T cells via the triple transfection method and purified via an iodixanol gradient. Confluency at transfection was between 80% and 90%. Media was replaced with pre-warmed media 2h before transfection. Each virus was produced in five 15 cm plates, where each plate was transfected with 10 µg of pXR-capsid (pXR-1, pXR-5, and pXR-9), 10 µg of recombinant transfer vector, and 10 µg of pHelper vector using polyethylenimine (PEI; 1 mg/mL linear PEI in DPBS [pH 4.5], using HCl) at a PEI:DNA mass ratio of 4:1. The mixture was incubated for 10 min at room temperature and then

applied dropwise onto the media. The virus was harvested after 72 h and purified using an iodixanol density gradient ultracentrifugation method. The virus was then dialyzed with 1x PBS (pH 7.2) supplemented with 50 mM NaCl and 0.0001% of Pluronic F68 (Thermo Fisher Scientific) using 50-kDa filters (Millipore) to a final volume of ~100 μ L and quantified by qPCR using primers specific to the ITR region, against a standard (ATCC VR-1616): AAV-ITR-F: 5' -CGGCCTCAGTGAGCGA-3' and AAV-ITR-R: 5' -GGAACCCCTAGTGATGGAGTT-3'

Animals Experiments

All animal procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Diego. All mice were acquired from Jackson Laboratory. Two-month-old adult male C57BL/6 mice (25-30g) were housed with food and water provided *ad libitum*, under a 12 h light/dark cycle with up to 5 mice per cage. All behavioral tests were performed during the light cycle period.

Intrathecal AAV Injections

Anesthesia was induced with 2.5% isoflurane delivered in equal parts O₂ and room air in a closed chamber until a loss of the righting reflex was observed. The lower back of mice was shaven and swabbed with 70% ethanol. Mice were then intrathecally (i.t.) injected using a Hamilton syringe and 30G needle as previously described¹⁰⁴ between vertebrae L4 and L5 with 5 μ L of AAV for a total of 1E+12 vg/mouse. A tail flick was considered indicative of appropriate needle placement. Following injection, all mice resumed motor activity consistent with that observed prior to i.t. injection.

Pain Models

Intraplantar carrageenan injection: Carrageenan-induced inflammation is a classic model of edema formation and hyperalgesia^{105–107}. 21 days after AAV pre-treatment, anesthesia was induced as described above. Lambda carrageenan (Sigma Aldrich; 2% (W/V) dissolved in 0.9% (W/V) NaCl solution, 20 μ L) was subcutaneously injected with a 30G needle into the plantar (ventral) surface of the ipsilateral paw. An equal amount of isotonic saline was injected into the contralateral paw. Paw thickness was measured with a caliper before and 4h after carrageenan/saline injections as an index of edema/inflammation. Hargreaves testing was performed before injection (t=0) and (t=

30, 60, 120, 240 minutes and 24 hours post-injection). The experimenter was blinded to the composition of treatment groups. Mice were euthanized after the 24-hour time point.

Paclitaxel-induced neuropathy: Paclitaxel (Tocris Biosciences, 1097) was dissolved in a mixture of 1:1:18 [1 volume ethanol/1 volume Cremophor EL (Millipore, 238470)/18 volumes of sterilized 0.9% (W/V) NaCl solution]. Paclitaxel injections (8 mg/kg) were administered intraperitoneally (i.p.) in a volume of 1 mL/100 g body weight every other day for a total of four injections to induce neuropathy (32 mg/kg), resulting in a cumulative human equivalent dose of 28.4–113.5 mg/m² as previously described⁶⁷. Behavioral tests were performed 24 hours after the last dosage.

Intrathecal BzATP injection: BzATP (2'(3')-O-(4-Benzoylbenzoyl) adenosine 5'-triphosphate triethylammonium salt) was purchased from Millipore Sigma and, based on previous tests, was dissolved in saline (NaCl 0.9%) to final a concentration of 30 nmol. Saline solution was also used as a vehicle control and both were delivered in a 5 µL volume. Intrathecal injections were performed under isoflurane anesthesia (2.5%) by lumbar puncture with a 30-gauge needle attached to a Hamilton syringe.

Behavioral tests

Mice were habituated to the behavior and to the experimental chambers for at least 30 min before testing. As a positive control, gabapentin (Sigma, G154) was dissolved in saline solution and injected i.p. at 100 mg/kg/mouse.

Thermal Withdrawal Latency (Hargreaves Test): To determine the acute nociceptive thermal threshold, the Hargreaves' test was conducted using a plantar test device (Ugo Basile, Italy)¹⁰⁸. Animals were allowed to freely move within a transparent plastic enclosure (6 cm diameter × 16 cm height) on a glass floor 40 min before the test. A mobile radiant heat source was then placed under the glass floor and focused onto the hind paw. Paw withdrawal latencies were measured with a cutoff time of 30 seconds. An IR intensity of 40 was employed. The heat stimulation was repeated three times on each hind paw with a 10 min interval to obtain the mean latency of paw withdrawal. The experimenter was blinded to composition of treatment groups.

Tactile allodynia: For the BzATP pain model, tactile thresholds (allodynia) were assessed 30 minutes, 1, 2, 3, 6, 24 hours after the BzATP injection. For the Paclitaxel model, tactile thresholds (allodynia) were assessed 24 hours and 29 days after the last Paclitaxel injection. Forty-five minutes before testing, mice were placed in clear plastic wire mesh-bottom cages for acclimation. The 50% probability of withdrawal threshold

was assessed using von Frey filaments (Seemes Weinstein von Frey anesthesiometer; Stoelting Co., Wood Dale, IL, USA) ranging from 2.44 to 4.31 (0.04–2.00 g) in an up-down method, as previously described¹⁰⁷.

Cold allodynia: Cold allodynia was measured by applying drops of acetone to the plantar surface of the hind paw as previously described^{109,110}. Mice were placed in individual plastic cages on an elevated platform and were habituated for at least 30 min until exploratory behaviors ceased. Acetone was loaded into a one mL syringe barrel with no needle tip. One drop of acetone (approximately 20 μ L) was then applied through the mesh platform onto the plantar surface of the hind paw. Care was taken to gently apply the bubble of acetone to the skin on the paw without inducing mechanical stimulation through contact of the syringe barrel with the paw. Paw withdrawal time in a 60s observation period after acetone application was recorded. Paw withdrawal behavior was associated with secondary animal responses, such as rapid flicking of the paw, chattering, biting, and/or licking of the paw. Testing order was alternated between paws (i.e. right and left) until five measurements were taken for each paw. An interstimulation interval of 5 minutes was allowed between testing of right and left paws.

Tissue collection

After the 24-hour time carrageenan time point, spinal cords were collected via hydroextrusion (injection of 2 mL of iced saline through a short blunt 20 gauge needle placed into the spinal canal following decapitation). After spinal cord tissue harvest, the L4-L6 DRG on each side were combined and frozen as for the spinal cord. Samples were placed in DNase/RNase-free 1.5 mL centrifuge tubes, quickly frozen on dry ice, and then stored at -80°C for future analysis.

Gene Expression Analysis and qPCR

RNA from Neuro2a cells was extracted using RNeasy Kit (QIAGEN; 74104) and from DRG using RNeasy Micro Kit (QIAGEN; 74004). cDNA was synthesized from RNA using Protoscript II Reverse Transcriptase Kit (NEB; E6560L). Real-time PCR (qPCR) reactions were performed using the KAPA SYBR Fast qPCR Kit (Kapa Biosystems; KK4601), with gene-specific primers in technical triplicates and in biological triplicates (Neuro2a cells). Relative mRNA expression was normalized to GAPDH levels and fold change was calculated using the comparative CT ($\Delta\Delta\text{CT}$) method and normalized to GAPDH. Mean fold change and SD were calculated using Microsoft Excel.

Western Blot

Neuro2a cells were thawed and protein extraction was performed with RIPA buffer (25mM Tris•HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; Thermo Fisher 89900) supplemented with protease inhibitors (Sigma P8849). Total protein was quantified with BCA protein assay kit (Thermo Fisher 23225), and 40 µg of protein were loaded into 4-15% polyacrylamide gels (BioRad 4561085). Proteins were transfer to a PVDF membrane (Thermo Fisher IB401001) and the membrane was blocked with 5% (W/V) blotting-grade blocker (Biorad 1706404) dissolved in TBS-T (Thermo Fisher, 28358 supplemented with 0.1% (V/V) Tween-20; BioRad 1610781). Membranes were then incubated overnight at 4°C with primary antibodies: anti-Na_v1.7 diluted 1:1000 (Abcam; ab85015) and anti-GAPDH (Cell Signaling, 2118) diluted 1:4000. Membranes were then washed three times with TBS-T and incubated for 1 h at room temperature with anti-rabbit horseradish-peroxidase-conjugated secondary antibody (Cell Signaling, 7074) diluted 1:20000. After being washed with TBST, blots were visualized with SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher) and visualized on an X-ray film.

RNAscope ISH Assays

The mCherry, and Na_v1.7 probes were designed by Advanced Cell Diagnostics (Hayward, CA). The mCherry probe (ACD Cat# 404491) was designed to detect 1480–2138 bp ([KF450807.1](#), C1 channel), and the Na_v1.7 (ACD Cat#313341), was designed to detect 3404–4576 bp of the *Mus musculus* Na_v1.7 mRNA sequence ([NM_018852.2](#), C3 channel). Before sectioning, DRG were placed into 4% PFA for 2 hours at room temperature, followed by incubation in 30% sucrose overnight at 4°C. Tissues were sectioned (12 µm thick) and mounted on positively charged microscopic glass slides (Fisher Scientific). All hybridization and amplification steps were performed following the ACD RNAscope V2 fixed tissue protocol. Stained slides were coverslipped with fluorescent mounting medium (ProLong Gold Anti-fade Reagent P36930; Life Technologies) and scanned into digital images with a Zeiss 880 Airyscan Confocal at 20x magnification. Data was processed using ZEN software (manufacturer-provided software).

Statistical analysis

Results are expressed as mean +/- standard error (SE). Statistical analysis was performed using GraphPad Prism (version 8.0, GraphPad Software, San Diego, CA, USA). Results were analyzed using Student's t-test (for differences between two groups), one-way ANOVA (for multiple groups), or two-way ANOVA with the Bonferroni *post hoc* test (for multiple groups time-course experiments). Differences between groups with $p < 0.05$ were considered statistically significant.

REFERENCES

1. Johannes, C. B., Le, T. K., Zhou, X., Johnston, J. A. & Dworkin, R. H. The Prevalence of Chronic Pain in United States Adults: Results of an Internet-Based Survey. *J. Pain* **11**, 1230–1239 (2010).
2. Souza, J. B. De *et al.* Prevalence of Chronic Pain, Treatments, Perception, and Interference on Life Activities: Brazilian Population-Based Survey. *Pain Res. Manag.* **2017**, (2017).
3. Fayaz, A., Croft, P., Langford, R. M., Donaldson, L. J. & Jones, G. T. Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. *BMJ Open* **6**, (2016).
4. Breivik, H., Collett, B., Ventafridda, V., Cohen, R. & Gallacher, D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. *Eur. J. Pain* **10**, 287–333 (2006).
5. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and E. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.* (2011). doi:10.17226/13172
6. Hudson, T. J. *et al.* Pharmacoepidemiologic analyses of opioid use among OEF/OIF/OND veterans. *Pain* **158**, 1039–1045 (2017).
7. Reid, M. C., Eccleston, C. & Pillemer, K. Management of chronic pain in older adults. *BMJ* **350**, h532 (2015).
8. Baumbauer, K. M. *et al.* Managing Chronic Pain in Special Populations with Emphasis on Pediatric, Geriatric, and Drug Abuser Populations. *Med. Clin. North Am.* **100**, 183–197 (2016).
9. Sapunar, D., Kostic, S., Banozic, A. & Puljak, L. Dorsal root ganglion - a potential new therapeutic target for neuropathic pain. *J. Pain Res.* **5**, 31–38 (2012).
10. Liem, L., van Dongen, E., Huygen, F. J., Staats, P. & Kramer, J. The Dorsal Root Ganglion as a Therapeutic Target for Chronic Pain. *Reg. Anesth. Pain Med.* **41**, 511–519 (2016).
11. Berta, T., Qadri, Y., Tan, P.-H. & Ji, R.-R. Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain. *Expert Opin. Ther. Targets* **21**, 695–703 (2017).
12. Abram, S. E. & Yaksh, T. L. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. *Anesthesiology* **80**, 383–91; discussion 25A (1994).

13. Chaplan, S. R., Bach, F. W., Shafer, S. L. & Yaksh, T. L. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. *Anesthesiology* **83**, 775–785 (1995).
14. Wallace, M. S., Dyck, J. B., Rossi, S. S. & Yaksh, T. L. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. *Pain* **66**, 69–77 (1996).
15. Wallace, M. S. *et al.* Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma—a report of a series. *Anesth. Analg.* **85**, 794–796 (1997).
16. Reimann, F. *et al.* Pain perception is altered by a nucleotide polymorphism in SCN9A. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 5148–5153 (2010).
17. Cox, J. J. *et al.* An SCN9A channelopathy causes congenital inability to experience pain. *Nature* **444**, 894–898 (2006).
18. Waxman, S. G. Painful Na-channelopathies: an expanding universe. *Trends Mol. Med.* **19**, 406–409 (2013).
19. Starobova, H. & Vetter, I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. *Front. Mol. Neurosci.* **10**, 174 (2017).
20. Han, C., Huang, J. & Waxman, S. G. Sodium channel Nav1.8: Emerging links to human disease. *Neurology* **86**, 473–483 (2016).
21. Sun, J. *et al.* SCN11A variants may influence postoperative pain sensitivity after gynecological surgery in Chinese Han female patients. *Medicine (Baltimore)*. **96**, e8149 (2017).
22. Castoro, R. *et al.* SCN11A Arg225Cys mutation causes nociceptive pain without detectable peripheral nerve pathology. *Neurol. Genet.* **4**, e255 (2018).
23. Bennett, D. L. H. & Woods, C. G. Painful and painless channelopathies. *Lancet. Neurol.* **13**, 587–599 (2014).
24. Faber, C. G. *et al.* Gain-of-function Nav1.8 mutations in painful neuropathy. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 19444–19449 (2012).
25. Faber, C. G. *et al.* Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. *Ann. Neurol.* **71**, 26–39 (2012).
26. Huang, J. *et al.* Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. *Brain* **137**, 1627–1642 (2014).
27. Huang, J. *et al.* Sodium channel Nav1.9 mutations associated with insensitivity to pain dampen neuronal excitability. *J. Clin. Invest.* **127**, 2805–2814 (2017).

28. Dib-Hajj, S. D., Black, J. A. & Waxman, S. G. Nav1.9: a sodium channel linked to human pain. *Nat. Rev. Neurosci.* **16**, 511–519 (2015).
29. Dib-Hajj, S. D., Yang, Y., Black, J. A. & Waxman, S. G. The Na(V)1.7 sodium channel: from molecule to man. *Nat. Rev. Neurosci.* **14**, 49–62 (2013).
30. Goldberg, Y. P. *et al.* Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. *Clin. Genet.* **71**, 311–319 (2007).
31. Yang, Y., Mis, M. A., Estacion, M., Dib-Hajj, S. D. & Waxman, S. G. Nav1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine. *Trends Pharmacol. Sci.* **39**, 258–275 (2018).
32. Kingwell, K. Nav1.7 withholds its pain potential. *Nature reviews. Drug discovery* (2019). doi:10.1038/d41573-019-00065-0
33. Hutchings, C. J., Colussi, P. & Clark, T. G. Ion channels as therapeutic antibody targets. *MAbs* **11**, 265–296 (2019).
34. Sun, H. & Li, M. Antibody therapeutics targeting ion channels: are we there yet? *Acta Pharmacol. Sin.* **34**, 199 (2013).
35. Bang, S. *et al.* Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7. *Neurosci. Bull.* **34**, 22–41 (2018).
36. Lee, J.-H. *et al.* A Monoclonal Antibody that Targets a Nav1.7 Channel Voltage Sensor for Pain and Itch Relief. *Cell* **157**, 1393–1404 (2014).
37. Cregg, R., Momin, A., Rugiero, F., Wood, J. N. & Zhao, J. Pain channelopathies. *J. Physiol.* **588**, 1897–1904 (2010).
38. Tabebordbar, M. *et al.* In vivo gene editing in dystrophic mouse muscle and muscle stem cells. *Science (80-.).* **351**, 407–411 (2016).
39. Nelson, C. E. *et al.* In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science (80-.).* **351**, 403–407 (2016).
40. Long, C. *et al.* Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science* **351**, aad5725 (2015).
41. Amoasii, L. *et al.* Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. *Science (80-.).* **362**, 86 LP – 91 (2018).
42. Yang, Y. *et al.* A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nat Biotech* **34**, 334–338 (2016).
43. Yin, H. *et al.* Therapeutic genome editing by combined viral and non-viral delivery

- of CRISPR system components in vivo. *Nat. Biotechnol.* **34**, 328–333 (2016).
44. Monteys, A. M., Ebanks, S. A., Keiser, M. S. & Davidson, B. L. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo. *Mol. Ther.* **25**, 12–23 (2017).
45. Gilbert, L. a *et al.* CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. *Cell* **154**, 442–451 (2013).
46. Gilbert, L. A. *et al.* Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. *Cell* **159**, 647–661 (2014).
47. Kearns, N. A. *et al.* Functional annotation of native enhancers with a Cas9–histone demethylase fusion. *Nat. Methods* **12**, 401 (2015).
48. Gaba, F. *et al.* Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. *Nucleic Acids Res.* **42**, e155–e155 (2014).
49. Thakore, P. I. *et al.* Highly specific epigenome editing by {CRISPR-Cas9} repressors for silencing of distal regulatory elements. *Nat Methods* **12**, 1143–1149 (2015).
50. Moreno, A. M. *et al.* *In situ* gene therapy via AAV-CRISPR-Cas9 mediated targeted gene regulation. *Mol. Ther.* (2018). doi:10.1016/j.ymthe.2018.04.017
51. Thakore, P. I. *et al.* RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. *Nat. Commun.* **9**, 1674 (2018).
52. Lupo, A. *et al.* KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions. *Curr. Genomics* **14**, 268–278 (2013).
53. Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 1156–1160 (1996).
54. Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F. 3rd. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 14628–14633 (1998).
55. Kim, H. J., Lee, H. J., Kim, H., Cho, S. W. & Kim, J.-S. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. *Genome Res.* **19**, 1279–1288 (2009).
56. Peterson, C. D. *et al.* AAV-Mediated Gene Delivery to the Spinal Cord by

- Intrathecal Injection. in *Methods in molecular biology* (Clifton, N.J.) **1950**, 199–207 (2019).
57. Hirai, T. *et al.* Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury. *Mol. Ther.* **22**, 409–419 (2014).
  58. Schuster, D. J. *et al.* Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. *Front. Neuroanat.* **8**, 42 (2014).
  59. Gregory, N. S. *et al.* An overview of animal models of pain: disease models and outcome measures. *J. Pain* **14**, 1255–1269 (2013).
  60. Black, J. A., Liu, S., Tanaka, M., Cummins, T. R. & Waxman, S. G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. *Pain* **108**, 237–247 (2004).
  61. Radhakrishnan, R., Moore, S. A. & Sluka, K. A. Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. *Pain* **104**, 567–577 (2003).
  62. Radhakrishnan, R., Bement, M. K. H., Skyba, D., Sluka, K. A. & Kehl, L. J. Models of muscle pain: carrageenan model and acidic saline model. *Curr. Protoc. Pharmacol.* **Chapter 5**, Unit 5.35 (2004).
  63. Zhang, H. & Dougherty, P. M. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. *Anesthesiology* **120**, 1463–1475 (2014).
  64. Chang, W. *et al.* Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. *Neurosci. Bull.* **34**, 4–12 (2017).
  65. Currie, G. L. *et al.* Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis. *PLoS Biol.* **17**, e3000243 (2019).
  66. Pacharinsak, C. & Beitz, A. Animal models of cancer pain. *Comp. Med.* **58**, 220–233 (2008).
  67. Toma, W. *et al.* Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. *Neuropharmacology* **117**, 305–315 (2017).
  68. Ford, A. P. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. *Purinergic Signal.* **8**, 3–26 (2012).

69. Boue-Grabot, E. & Pankratov, Y. Modulation of Central Synapses by Astrocyte-Released ATP and Postsynaptic P2X Receptors. *Neural Plast.* **2017**, 9454275 (2017).
70. Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. *Cell* **139**, 267–284 (2009).
71. Munoz, F. M. *et al.* Neuronal P2X7 receptor-induced reactive oxygen species production contributes to nociceptive behavior in mice. *Sci. Rep.* **7**, 3539 (2017).
72. Song, J. *et al.* The role of P2X7R/ERK signaling in dorsal root ganglia satellite glial cells in the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR). *Brain. Behav. Immun.* **69**, 180–189 (2018).
73. Horlbeck, M. A. *et al.* Nucleosomes impede Cas9 access to DNA in vivo and in vitro. *Elife* **5**, (2016).
74. Lu, Y. & Westlund, K. N. Gabapentin Attenuates Nociceptive Behaviors in an Acute Arthritis Model in Rats. *J. Pharmacol. Exp. Ther.* **290**, 214 LP – 219 (1999).
75. Jones, C. K., Peters, S. C. & Shannon, H. E. Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents. *J. Pharmacol. Exp. Ther.* **312**, 726 LP – 732 (2005).
76. Smith, I. *et al.* Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. *PLOS Biol.* **15**, e2003213 (2017).
77. Stojic, L. *et al.* Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. *Nucleic Acids Res.* **46**, 5950–5966 (2018).
78. Cai, W. *et al.* shRNA mediated knockdown of Nav1.7 in rat dorsal root ganglion attenuates pain following burn injury. *BMC Anesthesiol.* **16**, 59 (2016).
79. Cai, W. *et al.* MicroRNA-182 Alleviates Neuropathic Pain by Regulating Nav1.7 Following Spared Nerve Injury in Rats. *Sci. Rep.* **8**, 16750 (2018).
80. Eisenried, A., Klukinov, M., Yeomans, D. C. & Tzabazis, A. Z. Antihyperalgesic effect by herpes vector-mediated knockdown of Nav1.7 sodium channels after skin incision. *Neuroreport* **28**, 661–665 (2017).
81. Mohan, A. *et al.* Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. *Pain* **159**, 139–149 (2018).
82. Shao, J. *et al.* MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the rat. *Mol. Pain* **12**, (2016).

83. Pan, J., Lin, X.-J., Ling, Z.-H. & Cai, Y.-Z. Effect of down-regulation of voltage-gated sodium channel Nav1.7 on activation of astrocytes and microglia in DRG in rats with cancer pain. *Asian Pac. J. Trop. Med.* **8**, 405–411 (2015).
84. Samaranch, L. *et al.* Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. *Hum. Gene Ther.* **24**, 526–532 (2013).
85. Castle, M. J., Cheng, Y., Asokan, A. & Tuszynski, M. H. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion. *Sci. Adv.* **4**, eaau9859 (2018).
86. Bey, K. *et al.* Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. *Gene Ther.* **24**, 325–332 (2017).
87. Xia, Z., Xiao, Y., Wu, Y. & Zhao, B. Sodium channel Nav1.7 expression is upregulated in the dorsal root ganglia in a rat model of paclitaxel-induced peripheral neuropathy. *Springerplus* **5**, 1738 (2016).
88. Dalgarno, R., Leduc-Pessah, H., Pilapil, A., Kwok, C. H. & Trang, T. Intrathecal delivery of a palmitoylated peptide targeting Y382-384 within the P2X7 receptor alleviates neuropathic pain. *Mol. Pain* **14**, 1744806918795793 (2018).
89. Teixeira, J. M. *et al.* Diabetes-induced Neuropathic Mechanical Hyperalgesia Depends on P2X4 Receptor Activation in Dorsal Root Ganglia. *Neuroscience* **398**, 158–170 (2019).
90. Ito, G. *et al.* P2X7 receptor in the trigeminal sensory nuclear complex contributes to tactile allodynia/hyperalgesia following trigeminal nerve injury. *Eur. J. Pain* **17**, 185–199 (2013).
91. Zhang, J.-L. *et al.* Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. *Brain Res.* **1493**, 13–18 (2013).
92. Abdel-Salam, O. M. & Sleem, A. A. Study of the analgesic, anti-inflammatory, and gastric effects of gabapentin. *Drug Discov. Ther.* **3**, 18–26 (2009).
93. Niethammer, M. *et al.* Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. *JCI insight* **2**, e90133 (2017).
94. Zahur, M., Tolo, J., Bahr, M. & Kugler, S. Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. *Front. Mol. Neurosci.* **10**, 142 (2017).

95. Aronson, S. J. *et al.* Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. *J. Hepatol.* **71**, 153–162 (2019).
96. Mrass, P. & Weninger, W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. *Immunol. Rev.* **213**, 195–212 (2006).
97. Wilson, E. H., Weninger, W. & Hunter, C. A. Trafficking of immune cells in the central nervous system. *J. Clin. Invest.* **120**, 1368–1379 (2010).
98. Samaranch, L. *et al.* AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. *Mol. Ther.* **22**, 329–337 (2014).
99. Samaranch, L. *et al.* Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. *Hum. Gene Ther.* **23**, 382–389 (2012).
100. Su, S. *et al.* MiR-30b Attenuates Neuropathic Pain by Regulating Voltage-Gated Sodium Channel Nav1.3 in Rats. *Front. Mol. Neurosci.* **10**, 126 (2017).
101. de Moor, J. S. *et al.* Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. *Cancer Epidemiol. Biomarkers Prev.* **22**, 561–570 (2013).
102. Staff, N. P., Grisold, A., Grisold, W. & Windebank, A. J. Chemotherapy-induced peripheral neuropathy: A current review. *Ann. Neurol.* **81**, 772–781 (2017).
103. Manchikanti, L., Malla, Y., Cash, K. A., Pampati, V. & Hirsch, J. A. Comparison of effectiveness for fluoroscopic cervical interlaminar epidural injections with or without steroid in cervical post-surgery syndrome. *Korean J. Pain* **31**, 277–288 (2018).
104. Ichikizaki, K., Toya, S. & Hoshino, T. A New Procedure For Lumbar Puncture In The Mouse (Intrathecal Injection) Preliminary Report. *Keio J. Med.* **28**, 165–171 (1979).
105. Lucas, K. K., Svensson, C. I., Hua, X.-Y., Yaksh, T. L. & Dennis, E. A. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. *Br. J. Pharmacol.* **144**, 940–952 (2005).
106. Svensson, C. I. *et al.* Spinal phospholipase A2 in inflammatory hyperalgesia: Role of the small, secretory phospholipase A2. *Neuroscience* **133**, 543–553 (2005).
107. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. *J. Neurosci. Methods*

- 53**, 55–63 (1994).
108. Hargreaves, K., Dubner, R., Brown, F., Flores, C. & Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* **32**, 77–88 (1988).
  109. Guindon, J., Deng, L., Fan, B., Wager-Miller, J. & Hohmann, A. G. Optimization of a Cisplatin Model of Chemotherapy-Induced Peripheral Neuropathy in Mice: Use of Vitamin C and Sodium Bicarbonate Pretreatments to Reduce Nephrotoxicity and Improve Animal Health Status. *Mol. Pain* **10**, 1744–1756 (2014).
  110. Ward, S. J., Ramirez, M. D., Neelakantan, H. & Walker, E. A. Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. *Anesth. Analg.* **113**, 947–950 (2011).